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ABSTRACT 
 
The role of platelets in capturing circulating cells from flow in vivo an intravital microscopy study 
using laser –induced model of thrombosis in the murine cremaster muscle. 
ASHRAF. A 
 
Centre of Cardiovascular Sciences, School of Clinical and Experimental Medicine, College of Medical 
and Dental Sciences, University of Birmingham, UK. 
 
Literature has increasingly shown how platelets may have roles beyond haemostasis. Platelet related 
health problems are seen in cancer patients on many occasions. Therefore, there is a possible 
relationship between platelets and cancer metastasising through the blood stream.  Additionally, 
stem cell homing is an important aspect of stem cell therapy. For tissue regeneration to initiate, a 
sufficient number of stem cells must adhere to the injured sites. Present literature has shown that 
the low level of stem cell homing is a problem. Platelets are found at the site of injured tissues, so 
understanding the interactions between stem cells and platelets will enable research to be carried 
out to enhance homing mechanisms. In this study microcirculation was examined under an intravital 
microscope. A laser injury was induced causing damage to the blood vessels within the cremaster, 
which caused platelets to become adherent to the damaged area and form a thrombus. The labelled 
stem or tumour cells would then be perfused through in a single dose 1x106 cells when using 
haematopoietic stem cells or lewis lung carcinoma cells, and 5x105 cells when using mesenchymal 
stem cells. Results obtained demonstrated low levels of adherence between platelets and both types 
of stem cells and no adherence was observed between platelets and the tumour cells. Although this 
investigation has not provided any significant evidence of platelets interacting with stem cell or 
tumour cells, much literature has demonstrated their interactions and resulting therapeutic effects. 
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1.0 INTRODUCTION 
 
1.1 Platelets – their role beyond haemostasis 
Platelets are recognised as a key component in haemostasis and thrombosis and therefore 
play a very important role in the prevention of blood loss when tissues are injured. 
However, the literature has increasingly shown that platelets may have roles beyond those 
initially recognised. These include a role in promoting inflammatory responses and also in 
the maintenance of vascular integrity. Furthermore, recent literature has identified that 
platelets may be involved in various other processes that are not commonly associated with 
platelets including angiogenesis, tumour progression and metastasis (Jurasz et al., 2004; 
Smyth et al., 2009). Of all these additional roles identified for platelets, their ability to 
physically interact with or modulate the adhesion of other circulating cells has received the 
most attention.  A number of recent studies using mouse models have shown how platelets 
have the ability to interact with leukocytes and progenitor cells which can be recruited by 
platelets to sites of inflammation and vascular injury. Results from such studies have 
provided evidence for the involvement of platelets in many diseases and conditions 
including acute lung injury, atherosclerosis, hepatitis, sepsis, vascular restenosis and 
transplant rejection (Smyth et al., 2009). 
Bioactive mediators that are stored and released by platelets provide them with the ability 
to affect the functions of various cells. Upon platelet activation the three storage 
compartments found within platelets, α-granules, dense granules and lysosomes, release 
their contents. This occurs during exocytosis, which results in proteins being delivered into 
the blood circulation. The composition of the platelet membrane is also altered during this 
process. This further results in P-selectin expression on the cell surface, along with an 
elevation in the number of integrins αIIbβ3 [glycoprotein (GP) IIb-IIIa] molecules. One of the 
main roles of platelets beyond haemostasis is their ability to interact with leukocytes. The 
exposure of P-selectin is vital for this platelet-leukocyte interaction to occur. This is because 
the initial interaction between platelets and leukocytes is mediated by the P-selectin 
receptor.  P-selectin expressed on activated platelet cell surfaces also cause leukocytes to 
roll on the endothelium layer in the blood vessels which also express the P-selectin, the P-
selectin glycoprotein ligand 1(PSGL1) is also of importance in this process (Ley et al., 2007).  
The most abundant immune cell type is the neutrophils. Roughly 5 x 1010 – 10 x 1010 new 
neutrophils are formed in the bone marrow. They spend most of their time in the bone 
marrow; only 2% of neutrophils are found in the bloodstream with the average life span of 
5.4 days, once they migrate to tissues after activation they survive for around 1-2 days. 
Neutrophils are part of the innate immune response forming the first line of defence against 
fungal and bacterial pathogens (Christian et al., 2011).The recruitment of neutrophils, 
recirculation of lymphocytes and monocyte trafficking all require adhesion and 
transmigration through blood-vessel walls. There are 3 steps involved in this; rolling, 
activation and firm adhesion (Ley et al., 2007).Platelets have been identified to interact with 
neutrophils during inflammation and thrombosis. Interaction between these two cells can 
be initiated by activation of either the platelet or the neutrophil. This leads to a distinctive 
pattern of adhesion. The P-selectin on the platelet and the b2 integrin CD11b/CD18 are 
responsible for mediating the adhesion between the two cells, when they are activated 
either primarily or secondarily (Brown et al., 1998). The adhesion molecules play an 
important role in the interaction of platelets and circulating cells (Li., 2008; Smyth et al., 
2009; Yang et al., 1999).  
Although we know a lot about platelet -leukocyte interactions, less is known about their 
ability to influence the recruitment of other cells such as therapeutic stem cells or 
pathogenic tumour cells. 
Emerging evidence has shown the potential for platelets to also interact with cancer cells. 
Platelets from the blood flow have been identified to be involved in aiding cancer metastasis 
via tumour cell induced platelet aggregation (TCIPA). Metastasis is the process in which 
cancer cells migrate to areas of the body through blood flow. Cancer cells are more likely to 
migrate and form a secondary tumour in organs that have a larger blood supply as a higher 
number of cancer cells would migrate to that area. Tumour cell induced platelet aggregation 
has many advantages for tumour survival and also for successful metastasis. Platelets coat 
the tumours and protect it from TNF-α cytotoxicity and also shields the tumours from shear 
forces that are capable of causing damage (Jurasz et al., 2004; Placke et al., 2012;  Smyth et 
al., 2009).  ADP has been identified to be a (TCIPA) stimulator as it contributes to (TCIPA) 
induced by many different cancers such as small cell lung cancer, breast cancer, and 
melanoma. It has been identified that during breast cancer induced (TCIPA) ADP released 
caused aggregation of platelets via the activation of P2Y12 purinergic receptor (Alonso-
Escolano  et al., 2004). 
Inhibition of the platelets tumour cell interaction would help cancer therapy along with 
lowering the levels of metastasis caused by platelets.  Additionally, increasing stem cell 
infusion at this point may play a role in lowering platelet induced metastasis, which could be 
beneficial in cancer therapy. In relation to cancer therapy, MSCs have been identified to 
migrate to areas where damaged cells are in the process of progressing into cancer cells in 
glioblastoma related studies. Further research would be required to fully understand 
(TCIPA) and the leading tumour progression in different cancer cell lines. Furthermore, 
combining the two areas of research, platelet and tumour cell interactions and stem cell and 
tumour cell interactions, would be valuable (Courtney et al., 2013; Buergy et al., 2012; 
Jurasz et al., 2004).  
Platelets have been recognised to adhere to damaged sites of endothelium as the sub-
endothelial components are exposed, such as von Willebrand factor (vWf) and collagen. 
Since platelets are often identified to have the ability to adhere to injured tissues, they may 
also have the ability to specifically guide stem cells for regenerative purposes to injured 
sites. Currently, no in vivo research has been carried out to investigate if circulating cells 
specifically prefer to bind to activated inflamed endothelium, or to platelets that are already 
adherent to the blood vessels. Platelets normally adhere to the vessel wall after injury. 
Injury in the vessel wall causes the tissue collagen and plasma to be exposed, which causes 
platelets to adhere to initiate the clot formation in order to repair the damage. These blood 
cells may possibly be involved in the recruitment of MSCs, HSCs and progenitor cells to sites 
of injury. Additionally, it is not yet apparent if all circulating cells interact with platelets that 
are already adherent to the blood vessels to the same degree, or if specific cells interact to a 
greater degree due to the possible presence of specific adhesion molecules at their cell 
surface (Kavanagh et al., 2011 (a)). 
 
 
 1.2 Stem cell recruitment  
Multipotent hematopoietic stem cells (HSCs) are derived from the bone marrow. They have 
been recognised to maintain haemostasis via continuously replenishing the blood, including 
leukocytes, lymphocytes, erythrocytes and platelets through self renewal. However, these 
cells are quite rare, even though these cells have such important roles in the body. 
Literature has identified that 0.01% present characteristics of HSC in murine BM (Gentile et 
al., 2013; Kavanagh et al., 2011(b)(c)).  The fact that HSC are so rare is a major negative 
issue in research. The low availability results in limitation when investigating HSCs for their 
therapeutic abilities in vivo. Studies have shown the requirement of 20-30 donor mice to 
provide approximately 1.5x105 cells, which would only be sufficient for one intravital 
experiment, which are experiments that are carried out using an intravital microscope to 
the study microcirculation in vivo (Massberg et al.,2006). 
 
HPC-7 is an immortalised HSC cell line. This cell line is produced by transfecting murine 
embryonic SCs with the gene LHχ2 (Pinto et al., 1998). HPC-7 display similar characteristics 
as primary HSC. It has been demonstrated in recent studies that HPC-7 also express 
adhesion molecules that are present on primary HSCs. These include CD18 and CD49d. 
Therefore, HPC-7 have been previously used to model hepatic HSC recruitment (Kavanagh et 
al., 2010). 
Recently, literature has also shown that stem cells HPC-7 may be of use in therapy for tissue 
regeneration after injury.  A recent study demonstrated HPC-7 adherence to injured murine 
intestines in vivo. It was identified that after ischemia at 30 minutes and reperfusion at 90 
minutes, infusion of 2x106 HPC-7 increased the level of HPC-7 recruitment significantly 
(Kavanagh et al., 2013(a)). Although stem cell therapy has been associated with some 
clinical success, further research is still required in order to understand how these cells are 
recruited to sites of injury and if they interact with other circulating cells or the 
endothelium.  
Inflammatory disorder incidences are increasing within the western world. In relation, their 
treatments are not effective long term (Garcia et al., 2010). Literature has shown HPC-7 
have the potential to be clinically beneficial for inflammatory disorders, such as Crohn’s 
patients and colitis (Kavanagh et al., 2011(a)).  Anti inflammatory factors and growth factors 
such as tissue growth factor –β1 (TGF-β1), stem cell factor (SCF), fibroblast growth factor 
(FGF), epithelial growth factor (EGF), vascular endothelial growth factor (VEGF) and platelet 
derived growth factor (PDGF)  are released from HSCs when they are exposed to pro-
inflammatory mediators within inflamed tissues. Studies have shown recruitment of HPC-7 
to injured liver, kidney and gut, which demonstrated that recruitment of HPC-7 is possible 
(Kavanagh et al., 2010; Kavanagh et al., 2013(a)). 
Cellular interactions mediating recruitment of HSC to injured sites have shown the 
involvement of CD49d. Recent studies have shown CD49d (α4 subunit of α4β1 integrin) 
/VCAM-1 pathway involved in HSC recruitment to murine injured liver and (IR) injured 
murine small intestines in vivo (Kavanagh et al., 2010). Furthermore, literature increasingly 
demonstrates how platelets may be involved in stem cell (HSC, MSC and progenitor) 
recruitment to injured sites ( Kavanagh et al., 2011(a); Kavanagh et al., 2013(b); Strauer and 
Kornowski, 2003). Progenitor cells have been recognised not to have the ability to directly 
bind to the sub-endothelial and therefore, the involvement of platelets has been seen as 
vital to mediate their interaction (Massberg et al.,2006). Additionally, integrins found on the 
surface of progenitor cells have been identified to be activated by the ligand CXCL12, 
secreted by activated platelets (Massberg et al.,2006; Peled et al.,2009). CXCL12 is the 
accompanying ligand of G- protein coupled chemokine receptor CXCR4 and this receptor has 
been identified to play a vital role in the recruitment of HSC to sites of injury (Sipkins et al., 
2005). 
Literature has shown, that the method of stem cell delivery is also related to the level of 
engraftment at sites of injury (Strauer and Kornowski, 2003). Stem cell homing is an 
important aspect of stem cell therapy as a sufficient number of stem cells must adhere to 
the blood vessels within injured sites for tissue regeneration to occur. Present literature has 
shown that the low level of stem cell homing is a problem (Kavanagh et al., 2011(a); 
Kavanagh et al., 2013(a)). Understanding the molecular adhesive factors would help us 
understand the mechanisms underlying cellular interactions of stem cells (Strauer and 
Kornowski, 2003). This would provide the basis to allow further work in enhancing stem cell 
recruitment to injured sites and consequently resulting in possible enhancement of tissue 
repair.  
Mesenchymal stem cells have also been identified to posses the ability to migrate to target 
areas such as gliomas. MSC can be extracted from adipose tissue, bone marrow, umbilical 
cord and dental pulp but those used for research purposes and in early clinical studies have 
been derived primarily from BM and adipose tissue due to the ease of isolation and 
expansion from these sites. MSCs are also being considered for cancer treatment as they 
can be used to aid the delivery of drugs used in cancer therapy (Courtney et al., 2013).  MSC 
have been associated with having an anti cancer effect, which has been demonstrated by 
MSCs being identified to home at the site of tumour development in many cancers such as; 
colon, breast, ovarian, melanoma, prostate and gliomas (Courtney et al., 2013). However, 
further research is required to confirm their anti cancer effect. MSC have also been 
identified as a potential component in repairing diabetic wounds. Diabetic wounds have 
impaired blood supply and MSCs have shown potential in enhancing angiogenesis and 
improving wound healing in comparison to untreated wounds (O'Loughlin et al., 2013).  
Literature has also identified that due to the larger size of MSCs, recruitment is more 
difficult as they become stuck within capillaries and therefore it is more likely that an 
insufficient number will reach the injured site (Kavanagh et al., 2013(b)). In comparison, 
HSCs are smaller in size and have not been identified to be caught in capillaries and 
therefore a higher number of these stem cells are more likely to adhere to the injured area. 
Regardless of the size of these stem cells they have both been identified to be of 
therapeutic use (Kavanagh et al., 2011(a); Kavanagh et al., 2013(b)). 
 However, knowledge of the underlying mechanisms, of the recruitment of stem cells is 
limited and the involvement of platelets during stem cell recruitment still needs to be better 
understood and therefore needs to be further investigated using in vivo models. 
 
1.3 LLC- Lewis lung cell carcinoma 
In USA 20% of deaths caused by cancer are due to lung related cancers. Although, there are 
many treatments and diagnostic techniques that have been improved over the years the 5 
year survival rate in total for all lung cancer patients is a low 15%. Furthermore, the rate 
lowers to 2% if the patients are suffering from cancer metastasis (Morrison et al.,2012). 
Literature has demonstrated glycosaminoglycans to be attached to tumour cell surfaces via 
proteoglycans. These have been identified to be involved in cancer metastasis. The 
metastasis of lung carcinoma cells was observed to be decreased by preadministration of 
chondroitin sulphate unit E or by the use of phage display antibody specific for CS-E. 
However, the underlying mechanism resulting in metastasis needs to be investigated. 
Literature has discussed the involvement of platelets in cancer metastasis; it is possible that 
during this process of LLC metastasis, platelets may be involved at some point in enhancing 
the level of metastasis seen via (TCIPA). However, if the LLC tumour cells do not interact 
with platelets, it is likely that the metastasis is independent of platelet activity (Mizumoto 
and Sugahara, 2013). 
 
Therefore, understanding the process of metastasis in different cell lines and what might be 
involved in the process would lead to potential therapies. Inhibition of metastasis would 
lead to a better 5 year survival rate for lung cancer patients. Positive findings would be 
beneficial in forwarding research ideas for many other cancers and their progression 
(Morrison et al.,2012). 
 
1.4 Tumour cell recruitment and metastasis 
Patients suffering from cancer commonly display symptoms of thrombotic events which 
increase as the cancer progresses and metastasises (Gay et al., 2011). The specific forms of 
thrombosis seen in such patients are disseminated intravascular coagulation, pulmonary 
embolism and migratory thrombophlebitis (Gay et al., 2011). In many cases, signs of 
thrombosis may not always be detected, although an elevation in coagulation factors can 
still be identified. Since platelet related health problems are seen in cancer patients on 
numerous occasions, it is possible that platelets may interact with cancer cells and aid their 
metastasising through the blood stream and thus contribute to cancer progression. There 
has been much literature providing evidence of how platelets play an important role in 
cancer progression (Gay et al., 2011; Jurasz et al., 2004; Trousseau, 1865). 
Literature has shown tumours to have the ability to cause platelets to aggregate. This may 
explain the high number of thrombotic events seen in cancer patients. Cancer has ten 
recognised hallmarks; the growth signal autonomy, evasion of growth inhibitory signals, 
evasion of apoptosis, unlimited replicative potential, angiogenesis, invasion, metastasis, 
deregulated metabolism, unstable DNA, inflammation and evasion of the immune system 
(Hanahan and Weinberg; 2000). It has been demonstrated in recent studies, that tumours 
use platelets to evade the immune system in the body (Gay et al., 2011; Jurasz et al., 2004). 
Additionally, it is also found that platelets assist the adhesion of tumour cells to the vascular 
endothelium, providing growth factors which can be used by the tumour cells for growth 
(Gay et al., 2011; Jurasz et al., 2004) Understanding this process in vivo will aid the 
development of anti-platelet therapy which could possibly improve and enhance existing 
therapeutic methods in cancer. 
In order for cancer cells to metastasise they need to interact within the host 
microenvironment. This involves the circulation, lymphatic vessels and target tissues. The 
specific cells that are involved in the process of metastasis include endothelial cells, 
lymphocytes, macrophages, mast cells, fibroblasts, bone marrow derived progenitor cells 
and platelets. Currently to understand aspects of metastasis the most extensively studied 
cells are platelets (Gay et al., 2011; Joyce and Pollard, 2009). 
Trousseau was the first to identify the link between platelets and cancer in the middle of the 
nineteenth century. His finding led to the belief that tumours have the ability to activate 
platelets leading to the likelihood of spreading platelets from clots while they are forming 
(Gay et al., 2011; Trousseau, 1865). 
Platelet counts during different phases of cancer development are useful in the prediction 
of clinical outcomes. Thrombocytosis is linked with poor prognosis in many cancers, 
including colon, breast, lung, gastric, renal cervical endothelium, brain, pancreatic and 
ovarian cancer. Additionally, during chemotherapy the event of thrombocytopenia has been 
recognised to occur due to suppression of platelets being produced in the bone marrow, 
which could possibly be contributing to the anti-cancer effects of chemotherapy, as lower 
levels of platelets would cause less incidents of metastasis, as a result of less platelet-
tumour interactions (Gay et al., 2011; Kaushansky, 2008). 
Much research is required to gain a better understanding of tumour progression stages 
affected by platelet function, and at what point are the platelets adhesive functions 
involved in enhancement of tumour progression. Anti-platelet therapy may be of use in 
many treatments for many other diseases and therefore, its development through research 
and clinical trials should be focused on. 
 
1.5 Further research 
Looking at previous literature around this area it is obvious that there are many unanswered 
questions which require further research. It is important to understand the underlying 
mechanism of the interaction between platelets and circulating cells. Most of the studies 
that have been carried out are in vitro rather than in vivo. The techniques used within the 
current studies to investigate cellular interactions and interactions between circulating cells 
and damaged tissues, have included cannulation of a close artery to investigate the organ of 
interest. This is done by using the cannulated area for infusion of cells or other substances; 
investigating cellular interactions in a specific area of the mouse. This has been proven an 
efficient technique of investigation (Kavanagh et al., 2011(c)(d)). The cremaster has been 
used quite a lot through this sort of research mainly due to the fact that it is a good 
preparation to study microcirculation. Although the cremaster itself is rarely a target of 
injury or disease, but it is a good model of the vasculature of muscle. Therefore, it is an 
efficient model to use to investigate cellular interactions (Bagher and Segal, 2011). 
 In this study platelets and their ability to capture circulating cells from the blood flow, via 
intravital observations of the cremaster muscle in a mouse model will be investigated. It will 
be very useful to gain knowledge on how platelets capture circulating cells from the blood 
flow using this technique as it is more direct, it would show platelets and the cells of interest 
at the same time physically interacting with each other. This has not been shown previously 
in an in vivo study. This study will allow comparisons to be made in regards to the 
effectiveness of platelets in recruiting or interacting with different circulating cell 
populations.  Additionally, it will provide an insight on the behaviour of platelets in 
recruiting different cells, and if they are selective with regards to which cell they interact 
with.  Investigating the cellular interactions between platelets and tumours cells could 
possibly lead to a better understanding of how and why these cells interact and further lead 
to the development of methods to inhibit any interactions. Investigating the cellular 
interactions between stem cells and platelets may possibly lead to methods of enhancing 
their interactions to benefit the process of tissue regeneration possibly for many different 
diseases. 
 
1.6 Aims and Hypotheses 
 Platelets and HSCs will interact with each other following the development of laser-
induced thrombi within the mouse cremaster muscle microcirculation. 
 
 Platelets and MSC will interact in the cremaster after thrombi formation. 
 
 Platelets and mouse lung cancer cells will interact after thrombi formation. 
 
 HSCs will interact at a higher level in comparison to MSC. 
 
  The route of infusion will influence the interactions of platelets and circulating cells. 
 
 
 
 
 
 
 
 
 
2.0 METHODS 
 
2.1 Cell culture: Hematopoietic Stem Cells  
A stock solution of HSC specific culture media was made using 45ml of stem Pro 34 SFM, 
1.3ml stem cell supplement, 20μl(100ng per ml) stem cell factor (Life Technologies), 0.5ml 
penicillin/streptomycin and 0.5ml L-glutamine (P.A.A Laboratories). This culture media was 
changed every day by discarding the old media and adding fresh media to maintain a cell 
concentration of 1x106 cells/ml. After fresh media was added the flask was left in an 
incubator at 37˚C and 5% CO2. New media was added to the cells after being pelleted via 
centrifugation at 300g for 5 minutes and counted. The cells could then be distributed to a 
new flask once they reached confluence. In this study HPC-7 were used instead of primary 
HSCs. Prof. Leif Carlsson (University of Umeå, Sweden) gifted the HPC-7 cells used in this 
study. 
 
2.2 Cell culture: Mesenchymal Stem Cells 
The MSCs used were derived from the bone marrow. A stock solution of MSC specific 
culture media was made using 47ml Modified Eagles medium alpha- modification (α-MEM) 
(Sigma Aldrich) and 0.5ml foetal bovine serum , 0.5ml penicillin/streptomycin and  0.5ml L-
glutamine (P.A.A Laboratories) and 10μl (10ng per ml)transforming growth factor β (New 
England Biosciences). The culture media was changed 2-3 times per week when culturing 
these cells.  Cells were passaged after being trypsinised. New media was added to the cells 
after being pelleted via centrifugation at 300g for 10 minutes and counted. The cells could 
then be distributed to a new flask once they reached confluence. The flask was incubated at 
37˚C and 5% CO2. The MSC can only be used up until passage 9. 
 
2.3 Cell culture: Lewis lung carcinoma cell line 
The LLC cell line is a well established lung carcinoma derived from the lungs of C57BL/6 
mice. These cells are reported to be highly tumorigenic. Although, some studies suggest 
they are only weakly metastatic in mice. A stock solution of LLC specific culture media was 
made using 500ml Dulbecco’s modified eagles medium (DMEM), (Sigma Aldrich), 50ml 
foetal bovine serum, 5ml penicillin/streptomycin  and 5ml L-glutamine (P.A.A Laboratories). 
The culture media was changed was changed 2-3 times per week when culturing these cells. 
The cells were trypsinised before passaging as they were adherent. New media was added 
to the cells after being pelleted via centrifugation at 300g for 10 minutes and counted. The 
cells could then be distributed to a new flask once they reached confluence. The flask is 
then incubated at 37˚C and 5% CO2.  
 
2.4 Reagents 
Modified eagles medium alpha-modification (α-MEM), Dulbecco’s modified eagles medium 
(DMEM), Dulbecco’s phosphate buffered saline were all purchased from Sigma Aldrich. 
Carboxyfluorescein diacetete succinimidyl ester (CFSE), 0.25% Trypsin-EDTA, Stem Pro 34 
SFM, stem cell supplement and stem cell factor were purchased from Life Technologies. 
Foetal bovine serum, penicillin/streptomycin and L-glutamine were purchased from P.A.A 
Laboratories. Transforming growth factor β was purchased from New England Biolabs. 
2.5 Sterile conditions 
Keeping sterile conditions were important in order to avoid infecting the cells. Sterile 
conditions were kept by using 70% ethanol. Ethanol was sprayed on everything that was 
placed inside the Class-II culture cabinet. The cabinet created a sterile environment to work 
in. In order for the Class-II cabinet to be at a sterile state it must be switched on and left for 
at least 10-15 minutes prior to use. 
 
2.6 Cell counting 
A haemocytometer was used to count the cells (Figure 2.1), in order for the cells to be fed or 
split so they can divide efficiently. For this the media was discarded and the cells were 
washed using 5ml of PBS. The cells needed to be washed twice to make sure all the media 
was removed. Then 7ml of trypsin- EDTA solution (purchased from Life Technologies) was 
added to the flask of cells. After the trypsin was added, the flask needed to be returned to 
the incubator for around 10 minutes. This whole procedure was carried out so that the 
adherent cells can be detached from the bottom of the flask. The cells adhere to the bottom 
due to protein attachments. Trypsin is used as it is an enzyme that digests these proteins 
and releases the cells from the bottom of the flask. After 10 minutes the flask needs to be 
examined under a light microscope to confirm that the adherent cells have completely been 
detached from the bottom of the flask. If they have been released, on examination they will 
appear to be floating, if they are not, the flask needs to be returned to the incubator for a 
few more minutes until the adherent cells appear to be detached completely.  
Once the cells are detached completely 7 ml of full medium needs to be added to the flask 
which results in neutralisation of the trypsin activity. Before the media is added it needs to 
be warmed to 37˚C in a water bath for around 20 minutes. 
To count the cells a cover slip was placed on the haemocytometer 10 µl of cells was then 
added to 90 μl of trypan blue from which 10 μl of cells were pipetted into the 
haemocytometer. The haemocytometer was placed under a microscope and the cells could 
be counted. The trypan blue identifies all the dead cells by dying them blue and all the 
remaining viable cells can be counted. This allows accurate calculation of cell concentration.  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.1; Cell counting using a Haemocytometer; this figure shows how a 
haemocytometer would appear under a light microscope. The cells only need to be 
counted in the four regions, each region has sixteen squares. Only the cells within the 
borders should be counted. After counting the cells there should be four values, one for 
each region.  
 
 
 
 
 
2.7 Cell labelling 
Cells were pelleted by centrifugation at 300g; 5minutes for HSC and 10 minutes for MSC and 
tumour cells, the time and speed was kept the same every time the cells were centrifuged. 
Media was discarded and 2ml of PBS was added ready for centrifugation. Then cells were re-
suspended in 2 ml of PBS once again and added to a pre-prepared solution of 2ml of PBS 
with 2μl/5μm of CFSE. Cells were incubated at 37˚C for 10 minute. This was followed by a 
further addition of 6 ml of media and centrifugation. Cells were washed twice- each time 
with 2ml of media, followed by centrifugation each time. After the first wash cells were left 
to rest for 5minutes. Finally they were re-suspended in a desired volume ready for 
experimentation. Labelled cells were visible under fluorescent light (Figure 2.2). 
Carboxyfluorescein diacetete succinimidyl ester (CFSE) (purchased from Life Technologies) 
was used to label HSCs, MSCs and LLCs. For some experiments (Figure 3.6, 3.12, 3.17) the 
endogenous platelets were fluorescently labelled so that the thrombi formed could be 
clearly identified. This was done through injection into the carotid artery of a primary 
antibody against the platelet specific marker CD41 and a fluorescently labelled secondary 
antibody as shown in Table 2.1. 
 
Table 2.1 
Antibody Conjugate Clone Host Target Isotype Supplier Conc Volume 
Anti-CD41 N/A MwReg30 Rat Mouse IgG1, κ BD 
biosciences 
0.5mg/ml 20µl 
Polyclonal 
anti Rat 
IgG 
Alexa-555 Polyclonal Goat Rat IgG life 
technologies 
2mg/ml 40µl 
 
2.8 Animals 
In this study male C56BL/6 mice were used, at an average weight of 25g. Animals were 
housed at the BMSU (Biomedical service unit), University of Birmingham, under standard 
conditions according to Animals Scientific procedures Act 1986, under licence from the 
United Kingdom Home Office (PPL 40/3336) Animals were killed via Schedule 1- humane 
killing procedures; cervical dislocation. 
 
2.9 Surgical procedures 
Animals were anesthetised using an injection containing ketamine into the peritoneum (100 
mg/kg) and Xylazine (50mg/kg). Then a cannula was inserted into the trachea. This allows 
the mouse to breathe more easily during the investigation. Cannulation of the artery chosen 
for the route of infusion (femoral artery/carotid artery) was performed; the surgical 
procedures were carried out on animals at the average weight of 25 grams. The cremaster 
muscle was exteriorised and pinned open after exposing the testis through a scrotal incision, 
and clearing any connective tissue. The cremaster was continuously superfused with 
bicarbonate buffered saline (physiological solution- (pH 7.4; 37˚C) – gassed with 5% 
CO₂/95% N₂) to avoid loss of moisture. Through the chosen cannulated route of infusion 
substances such as CFSE labelled cells (HSC, MSC and LLC), anaesthesia, saline were 
administered. The animal was then left for 30 minutes to allow stabilisation and then was 
monitored under an intravital microscope. This procedure was non-recovery (Figure 2.3). 
 
  
 
 
 
 
 
 
 
Figure 2.2; To ensure injected cells could be visualised trafficking through the cremaster 
microcirculation, they were fluorescently labelled using CFSE, a dye which fluoresces 
green upon activation. In preliminary studies, 1x106 HPC-7 cells were injected via the 
femoral artery in the mice that had not undergone any additional procedures (ie. no laser 
ablation, TNF stimulation, ischemia-reperfusion injury or any pre-treatment of cells with 
H2O2). (A) Arteriole before the cells were infused. (B) A cell as it enters the vessel. (C) The 
cell moved across the arteriole. (D) The cell has left this field of view.  
  
 
Figure 2.3; Surgical procedure of femoral cannulation in a mouse model; (A) Area was 
exposed through an incision above the thigh to expose the artery and the vein. (B) Fat 
tissue preventing access to the femoral was cleared. (C)(D) Connective tissue was 
cleared to expose the femoral artery for separation from the vessels and nerves that 
surrounded. The femoral artery was tied off towards the foot and a loose knot was 
positioned at the opposite end. The femoral was clamped. An incision was made three 
quarters of the way down the femoral. (E) Cannula was inserted and a double knot was 
tied over the cannula to secure its position and the clamp was removed followed by the 
removal of air bubbles from the cannula. 
 
2.10 Intravital microscopy 
Once the animal had been surgically prepared the microcirculation was examined under an 
intravital microscope (Olympus BX-61WI). Laser ablations were induced to form thrombi in 
the blood vessels within the cremaster, which would cause platelets to become adherent to 
the damaged area. For this investigation laser induced injury was beneficial as the degree of 
the injury could be controlled (laser power (75) the power at which the laser hits the tissue, 
FRAP (Fluorescence recovery after photo-bleaching) size (10) the amount of area the laser 
makes direct contact with on the tissue, FRAP (Fluorescence recovery after photo-bleaching) 
repetition (15)) the number of times the laser contacts the tissue using the same power and 
size. Therefore, the level of thrombi formation could also be controlled and kept the same 
throughout the experiment, which allowed results obtained to be comparable.  
The labelled cells would then be perfused through in a single dose of 1x106 cells when using 
HSC or LLC, and 5x105 cells when using MSC. MSC were used at the concentration 5x105 
instead of 1x106 because their level of growth was lower in comparison to HSC and LLC and 
therefore, it was difficult to obtain high numbers of MSCs.  
The program Slide Book was used to capture the images on the intravital microscope. The 
cells were visibly green under fluorescent light. Using the intravital microscope the labelled 
cells that were adherent to the platelets forming the thrombi would be identified and using 
the data obtained (visual images) quantification was done offline. For all the results and 
data obtained the whole cremaster was scanned using the intravital microscope. Cells were 
characterised to form temporary adhesions if after adherence they unattached. The 
experimental model used in this investigation was beneficial, as valuable qualitative data 
could also be obtained. From this identification of obvious differences in the quality of the 
cremaster could be recognised and this may be of use in the analysis of the quantitative 
data obtained. Additionally, adherence of cells through the whole cremaster could be 
imaged. The effects of TNFα can also be identified via rolling leukocytes, therefore the 
efficiency of the intrascrotal injection can be visually confirmed.  
 
2.11 Data analysis 
The data was normalised because the number of thrombi formed in each cremaster varied. 
Method of normalisation; (highest number of thrombi formed during the 
investigation/actual number of thrombi formed within the cremaster)*number of adherent 
cells to thrombi. The data was expressed as mean ± SEM. For statistical analysis the 
following was used; unpaired t-tests; one way ANOVA; Bonferroni (Post Hoc test). The 
program used was PRISM. 
 
2.12 Method Development 
Initial experiments were carried out using naive cells, infused into a naive cremaster; MSC 
(N=3), HPC-7 (N=4), LCC (N=5). The second set of experiments were carried out using pre-
treated stem cells and TNFα treated cremaster, MSC (N=4) and HPC-7 (N=4). These were 
pre-treated with H₂O₂ for an hour before inserting them through the cannulated femoral 
artery. The animal was given 200μl/500ng TNFα via an intrascrotal injection 4 hours prior to 
ablation.  During this second set of experiments the LLC (N=5) were perfused through 500ng 
TNFα treated cremaster, but the LLC were not pre-treated. The TNFα treatment used 
resulted in a more inflamed microenvironment within the cremaster microcirculation. 
Previously the cells had no reason to become adherent, providing this environment 
increases their chances to become adherent. The route of infusion was investigated using 
the stem cells; MSC (N=4), HSC (N=4). These experiments investigated the difference in cell 
adherence when different routes of infusion were used therefore the carotid artery was 
cannulated instead of the femoral artery. The final sets of experiments were looking at the 
adherence of the cells when a different type of injury was induced; Ischemia for 30minutes 
and reperfusion for 90minute. When using the HSCs and MSCs the cells were pre-treated 
with H₂O₂ as in the previous experiments but LLC were not pre-treated. For these final set of 
experiments the cremaster was also not treated with TNFα; MSC (N=4), HSC (N=5), LLC 
(N=4). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Method summary  
3.0 RESULTS 
 
3.1 Naive HPC-7 show low adherence to thrombi generated in arterioles  
Studies were conducted using naive HPC-7 (N= 4), during which 15, 16, 16, and 15 thrombi 
were formed giving a total of 62 arteriole thrombi. Route of infusion used was the femoral 
artery and the following slide book settings were used: FRAP; size (7)-(10), repetition (15); 
laser power (75). Naive HPC-7’S were perfused to examine their interaction with platelets. 
Naive HPC-7 showed some adherence to thrombi formed. However, the number of HPC-7 
adherent was minimal in comparison to the number of HPC-7 perfused through the mouse 
model. Only 2 HPC-7 were adherent to 1 thrombi out of 62, and 4 cells out of 1x106 were 
adherent  within the capillaries in the cremaster (adherent cells to thrombi/field: 0.6 ± 0.62; 
Figure 3.3).  
 
3.2 HPC-7 Show temporary adhesion to thrombi when stimulated with H₂O₂ and TNFα 
treated cremaster 
Studies were conducted using HPC-7 that were pre-treated with H₂O₂ and the cremaster 
was treated with TNFα (N= 4), during which 9, 15, 15 and 20 thrombi were formed giving a 
total of 69 arteriole thrombi and the femoral artery was used as the route of infusion.  
Additional studies were conducted using HPC-7 that were also pre-treated with H₂O₂ and 
the cremaster was also treated with TNFα (N= 4), during which 15, 14, 20 and 15 thrombi  
were formed giving a total of 59 arteriole thrombi but on this occasion the carotid artery as 
the route of infusion. Only 5 HPC-7 were adherent to 1 thrombi out of 69 thrombi, and 3 
cells out of 1x106 were adherent within the capillaries in the cremaster; only 1 HPC-7 was 
adherent to 1 thrombi out of 59 thrombi. HPC-7 became adherent to thrombi before 
breaking their attachments, possibly due to the pressure of blood flow in the arterioles 
(adherent cells to thrombi/field: 1.5 ± 1.50; Figure 3.4).  
Additional experiments were conducted in which HPC-7 were pre-treated with H₂O₂ and 
were perfused into an ischemia reperfusion injury mouse model (N=4), during which 16, 15, 
15 and 15 thrombi were formed giving a total of 61 arteriole thrombi and the carotid artery 
was used as the route of infusion.  2 cells out of 1x106 were adherent within the capillaries 
in the cremaster (adherent cells to cremaster/field: 0.5 ± 0.29; Figure 3.6). The following 
slide book setting were used for all these experiments: FRAP; size (10), repetition (15); laser 
power (75). 
 
3.3 Naive and pre-treated MSC show low adherence to thrombi generated in arterioles, 
however they do become trapped within capillaries in the cremaster 
Studies were conducted using naive MSCs (N=4), during which 15, 15, 15 and 15 thrombi 
were formed giving a total of 60 arteriole thrombi. The femoral artery was used as the route 
of infusion.  Additional studies were conducted using H₂O₂  pre-treated MSCs and TNFα 
treated cremaster (N=4), during which 17, 15, 14 and 15 thrombi were formed giving a total 
of 61 arteriole thrombi and the femoral artery was used as the route of infusion. Another 
set of experiments were conducted in which MSCs were also pre-treated with H₂O₂ and 
were perfused into TNFα treated cremaster (N=4), during which 15, 14, 20 and 15 thrombi 
were formed giving a total of 64 arteriole thrombi but, on this occasion carotid artery was 
used as the route of infusion. The following slide book setting were used: FRAP; size (10), 
repetition (15); laser power (75). Only 1 MSC was adherent to 1 thrombi out of 64 thrombi.  
These particular stem cells did not show much signs of adherence to thrombi even after 
being stimulated with H₂O₂ and the cremaster stimulated with TNFα (adherent cells to 
thrombi/field: 0.3 ± 0.33; Figure 3.9 and 3.10). However, due to the size of these specific 
stem cells, they did have the tendency to become stuck within small capillaries (Figure 3.12). 
 Another study was conducted using H₂O₂ pre-treated MSCs (N=4), during which 15, 15, 15 
and 16 thrombi were formed giving a total of 61 arteriole thrombi. The carotid artery was 
used as the route of infusion. MSCs once again did not become adherent to any of the 
thrombi generated even after inducing ischemia reperfusion injury prior to thrombi 
formation. However, cells did appear to be adherent within the capillaries (adherent cells to 
cremaster/field: 0.5 ± 0.29; Figure 3.12). The following slide book setting were used: FRAP; 
size (10), repetition (15); laser power (75). Naive MSC; 1 out of 5x105 were adherent within 
the capillaries in the cremaster. MSC H2O2 pre-treated and TNF-α treated cremaster 
(femoral infusion); 1 out of 5x105 were adherent within the capillaries in the cremaster. MSC 
H2O2 pre-treated and TNF-α treated cremaster (carotid infusion); 1 out of 5x10
5 were 
adherent within the capillaries in the cremaster. MSC H2O2 pre-treated and ischemia 
reperfusion; 2 out of 5x105 were adherent within the capillaries in the cremaster. 
 
  
 
3.4 No significant difference identified when perfusing cells through the carotid artery 
instead of the femoral artery  
Results from this investigation described earlier were used to investigate any differences in 
route of infusion. To confirm that the stem cells not becoming adherent was not due to the 
chosen route of administration, experiments were carried out using carotid artery 
cannulation (Figure 3.5 and 3.11). The cells were pre-treated with H₂O₂ and the mouse was 
injected using an intrascrotal injection in the testes with TNFα. Inserting cells via the femoral 
artery may have been causing cells to perfuse through too quick, possibly due to the force at 
which the cell were perfused, and also due to the femoral being a closer and more direct 
route into the flow within the cremaster. Therefore, the stem cells may have not been 
getting an opportunity to become adherent, due to the force of the cells allowing a low level 
of contact to the damaged vessels as they are perfused. Perfusing through the carotid artery 
as an alternative would not disturb the flow as much as when perfusing cells via the 
femoral. The cells would now be more likely to become adherent without any resistance 
due to flow pressure. However, these experiments had shown no significant difference in 
stem cell adherence levels, as mentioned earlier. 
 
3.5 Naive Lewis carcinoma cells do not adhere to thrombi generated within arterioles 
Studies were conducted using naive LLCs and a naive cremaster (N=5), 15, 12, 19, 15 and 20 
thrombi were formed giving a total of 81 arteriole thrombi. Another set of experiments 
were carried out using naive LLC and TNFα treated cremaster (N=5), during which 15, 15, 12, 
16 and 15 thrombi were formed giving a total of 73 arteriole.  LLC were perfused through 
the mouse model without any treatment to the cells or the mouse and they were also 
perfused through after stimulating the cremaster.  LLC did not show any adherence within 
the cremaster in any case, as the cells were identified moving past large thrombi without 
any interaction observed (Figure 3.15 and 3.16). However, inducing ischemia reperfusion in 
the mouse model resulted in adherence of cells within the capillaries. In this additional 
study naive LLC were used without any treatment to the cremaster (N=4), during which 15, 
15, 15 and 15 thrombi were formed giving a total of 60 arteriole. 3 out of 1x106 were 
adherent in the capillaries within cremaster; (adherent cells to cremaster/field: 0.75 ± 0.25; 
Figure 3.17). The following slide book settings were used for all the experiments: FRAP; size 
(10), repetition (15); laser power (75) and the carotid artery was used as the route of 
infusion for all the LLC experiments. 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 3.1; HPC-7 stem cells show low adherence to thrombi after laser injury induced thrombi 
formation. Animal received 1 x 106 HPC-7 cells, stained with CFSE. Results are presented as mean 
cells per cremaster ± SEM. No significant differences were seen between the following comparisons; 
(Naive cells, naive cremaster vs. H2O2 pre-treated cells, TNF-α pre-treated cremaster, femoral 
infusion), (Naive cells, naive cremaster vs. H2O2 pre-treated cells, TNF-α pre-treated cremaster, 
carotid infusion), (Naive cells, naive cremaster vs. H2O2 pre-treated cells, IR – injury, carotid infusion). 
No cell adherence was observed after H2O2 pre-treated cells, IR – injury, carotid infusion. 
 
 
  
 
 
 
 
Figure 3.2; HPC-7 stem cells show low adherence to the cremaster. Animal received 1 x 106 HPC-7 
cells, stained with CFSE. Results are presented as mean cells per cremaster ± SEM. No significant 
differences were seen between the following comparisons; (Naive cells, naive cremaster vs. H2O2 
pre-treated cells, TNF-α pre-treated cremaster, femoral infusion), (Naive cells, naive cremaster vs. 
H2O2 pre-treated cells, TNF-α pre-treated cremaster, carotid infusion), (Naive cells, naive cremaster 
vs. H2O2 pre-treated cells, IR – injury, carotid infusion). No cell adherence was observed after H2O2 
pre-treated cells, TNF-α pre-treated cremaster, carotid infusion. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.Naive HPC-7, naive cremaster (A) Three HPC-7 adherent to the arteriole in the absence of a 
thrombi. (B) Two HPC-7 adherent to a thrombi generated in the arteriole. One HPC-7 trapped within a 
capillary. (C) No HPC-7 adherent to thrombi generated in the arteriole. (D) No HPC-7 adherent to 
thrombi generated in venule.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4; Pre – Treated HPC-7, femoral infusion (A)(B)No HPC-7 adherent to thrombi’s generated 
in arteriole’s. (C) 1 HPC-7 trapped within a capillary. (D) No HPC-7  adherent to thrombi’s generated 
in arteriole’s.(E)1 HPC-7 trapped within a capillary.(F) 1 HPC-7 adherent to thrombi generated in 
arteriole. (G) Another HPC-7 moving towards the thrombi. (H) 2 HPC-7 are now adherent to the 
thrombi. (I) The second HPC-7 that became adherent to the thrombi in (H) has now unattached and 
moved away with flow. (J) The remaining adherent HPC-7 has also unattached itself and moved 
away with flow. (K) 3 HPC-7 adherent to thrombi. (L) All 3 HPC-7 have unattached and moved along 
with flow. (M) 1 HPC-7 trapped within a capillary. 
  
 
Figure 3.5; Pre-Treated HPC-7, carotid infusion (A)(B)(C)No HPC-7 adherent to thrombi generated in 
arteriole. (D) HPC-7 moving towards the thrombi. (E) No HPC-7 adherent to thrombi generated in 
arteriole. (F) 1 HPC-7 adherent to the thrombi. (G) The HPC-7 unattached and no longer adherent to 
the thrombi 
 
 
 
 
 
 
 Figure 3.6; Pre – treated HSC – Ischemia reperfusion injury(A) Cells move into the arteriole and pass 
the labelled thrombi. (B) No cells are adherent to the thrombi. (C) Cell adherent within capillary. 
 
 
 
 
  
 
 
 
 
 
Figure 3.7; MSC stem cells show very low adherence to thrombi after laser injury induced thrombi 
formation. Animal received 5 x 105 MSC cells, stained with CFSE. Results are presented as mean cells 
per cremaster ± SEM. Cell adherence was only observed after H2O2 pre-treated cells, TNF-α pre-
treated cremaster, carotid infusion. No cell adherence was observed after any of the other 
treatments. 
 
 
 
 
  
 
 
 
 
 
 
Figure 3.8; MSC stem cells show low adherence to the cremaster. Animal received 5 x 105 MSC cells, 
stained with CFSE. Results are presented as mean cells per cremaster ± SEM. No significant 
differences were seen between the following comparisons; (Naive cells, naive cremaster vs. H2O2 
pre-treated cells, TNF-α pre-treated cremaster, femoral infusion), (Naive cells, naive cremaster vs. 
H2O2 pre-treated cells, TNF-α pre-treated cremaster, carotid infusion), (Naive cells, naive cremaster 
vs. H2O2 pre-treated cells, IR – injury, carotid infusion). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9; Naive MSC (A) Thrombi prior to the perfusion of MSC (B) MSC move into the arteriole 
passing the thrombi. (C) No MSC adherent to thrombi generated in arteriole. (D) 1 MSC trapped 
within a capillary.(E) No MSC adherent to thrombi in arteriole.  
 
 
 
 
  
 
 
Figure 3.10; Pre – treated MSC, femoral infusion (A)(B)(C)No MSC  adherent to thrombi’s generated in 
arteriole’s. (D) 1 MSC trapped within a capillary. (E) MSC move into the arteriole passing the thrombi. (F) 
No MSC adherent to thrombi generated in arteriole.  
 
 
 
 
 
 
 
 
  
 
Figure 3.11; Pre-Treated MSC, carotid infusion (A) 1 MSC adherent to the thrombi. (B) The MSC 
unattached and no longer adherent to the thrombi. (C) No MSC adherent to thrombi generated in 
arteriole. (D) 1 MSC trapped within a capillary.(E)(F) No MSC  adherent to thrombi generated in 
arteriole.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12; Pre – treated MSC – Ischemia reperfusion injury (A) MSC’s perfused through cremaster 
(arteriole). (B)(C)(D) Thrombi generated in arteriole with no MSC’s attached. (E)(F) Cells stuck within 
the capillaries (G) Cells move into the arteriole and past the labelled thrombi. (H) No cells are 
adherent to the thrombi 
 
 
  
 
Figure 3.13; No significant differences between HPC-7 and MSC adherence to the cremaster. (A) 
HPC-7 stem cells are more likely to be adherent to thrombi in the cremaster after laser injury 
induced thrombi formation, in comparison to MSC stem cells. (B) HPC-7 stem cells are more likely to 
be adherent to thrombi cremaster in laser injury induced thrombi formation, in comparison to MSC 
stem cells, when infused through the femoral artery as no MSC adherence was observed in 
comparison. (C) HPC-7 stem cells adherent to the thrombi in the cremaster after laser injury induced 
thrombi formation, in comparison to MSC stem cells; infused through the carotid artery;  not 
significantly different . (D) Overall, in the conditions of H2O2 pre-treated cells and TNF-α pre-treated 
cremaster, femoral infusion resulted in more adherence in comparison to carotid infusion. Animal 
received 1 x 106 HPC-7 cells or 5x105, stained with CFSE. Results are presented as mean cells per 
cremaster ± SEM. No significant differences were seen in (A), (B), (C) and (D). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14; Lewis lung carcinoma cells show very low adherence to the cremaster. Animal received 
1 x 106 LLC cells, stained with CFSE. Results are presented as mean cells per cremaster ± SEM. Cell 
adherence was only observed after IR – injury, carotid infusion. No cell adherence was observed 
after any of the other treatments. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15;  Naive LLC (A) Thrombi beginning to form in arteriole. (B) Thrombi from (A) Further 
developed. (C) Lewis cells infused. (D) Cells move past thrombi and do not become adherent. (E)(F) 
No tumour cells adherent to thrombi’s generated in other arterioles. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16; LLC – Mouse TNF-α treated (A)(B)(C)(D) Thrombi generated in arteriole with no cells 
attached. (E) Rolling cells in arteriole as a result of TNF-α treatment. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17; LLC – Ischemia reperfusion injury (A)(B)Cells move into the arteriole and past the 
labelled thrombi. (C) No cells are adherent to the thrombi. (D) Cell adherent within capillary. 
 
 
 
 
 
 
 
 
 
 
4.0 DISCUSSION 
 
From this study it has been identified that platelets are not very successful at capturing 
trafficking cells from flow. This investigation confirmed low levels of interactions between 
platelets and HPC-7, and between platelets and MSC. However, no interactions between 
platelets and LLC were observed. Furthermore, data also demonstrated some adherence at 
very low levels of all three cell types within capillaries in the cremaster.  
1x106 naive HPC-7 were infused through a naive cremaster after laser induced thrombi 
formation. Very low adherence was observed. This could be due to the fact that, neither the 
cremaster, nor the HPC-7 were stimulated. Therefore, there was no reason for adherence to 
thrombi to occur. 
Stimulating both the cremaster and the stem cells was seen as the most appropriate 
experimental development. 1x106 HPC-7 were pre-treated with H2O2, and infused through 
the cremaster, which was stimulated with TNF-α. Adherence to thrombi was still observed 
to be low after quantification. The adherence observed with HPC-7 was temporary as a few 
seconds of adherence, was followed by the unattachment of the HPC-7. However, 
adherence was still greater than that identified in the naive cremaster using naive HPC-7. 
Interestingly, the increase identified was not statically significant. It is a possibility that the 
low levels of adherence could be a result of the cremaster not being stimulated enough.  
Ischemia reperfusion injury has been identified to simulate the cremaster at a higher level 
than TNF-α. Therefore, the next development was to use an ischemia reperfusion model. 
1x106 HPC-7 were pre-treated with H2O2  and were infused through the cremaster after 30 
minutes ischemia and 90 minutes of reperfusion. From data obtained, no adherence was 
identified however; studies previously carried out using similar techniques had shown high 
levels of adherence of HPC-7 within the cremaster in the absence of thrombi (Kavanagh et 
al., 2010; Kavanagh et al., 2013(a)). The major difference was the use of laser induced injury 
for thrombi formation. Directing towards the possibility of laser induced injury to be causing 
possible changes to the conditions within microenvironment.  This may be resulting in the 
possible alteration of the adhesive ability of the cremaster. 
Literature has shown, HSC derived from the bone marrow were observed to show a 
significant increase in adherence levels in ischemia reperfusion injury in the cremaster; due 
to unknown factors released during IR injury of renal injury. TNF-α enhanced recruitment of 
HSC in the cremaster significantly, but 1L-1β enhanced recruitment better than TNF-α 
(Kavanagh et al., 2011(a)). 
In Another study a specific type of HSC (HPC-7) were infused into C57BL/6 male mice and 
while observing the cremaster significant levels of adherence was observed following 
ischemia for 30 minutes and reperfusion for 90 minutes  when comparisons were made with 
the sham cremaster. Furthermore, TNF-α significantly increased adhesion of HPC-7 in the 
cremaster however, the dose of TNF-α used was different to the dose used in this 
investigation as it was much lower at 100ng/200μl (Kavanagh et al., 2013(b)). Other 
experiments which would have been a beneficial control would be saline injected mice in 
comparison to TNF-α injected mouse.  
Infusion through the femoral using pre-treated HPC-7 and IR injury was an important 
experiment which would be a direct comparison to other previous studies. In this study 
HPC-7 adherence seen was low in comparison to literature. One of the main differences 
being femoral infusion instead of carotid infusion, resulting in higher levels of adherence 
previously identified. 
5x105 naive MSC were infused through a naive cremaster after laser induced thrombi 
formation. No adherence was observed possibly due to the same reason concluded with the 
HPC-7; no stimulation of the stem cells or the cremaster, giving no reason for adherence to 
thrombi to occur. 
The cremaster and the stem cells were both stimulated for the next set of experiments. 
5x105 MSC were pre-treated with H2O2, and infused through the cremaster, which was 
stimulated with TNF-α. Adherence to thrombi was identified, but at a very low level. 
Ischemia reperfusion was the final experimental development made to provide a more 
adhesive microenvironment for the MSC. 5x105 MSC were pre-treated with H2O2  which 
were infused through the cremaster after 30 minutes ischemia and 90 minutes of 
reperfusion. From data obtained, once again like the HPC-7 no adherence was identified. 
Other than the possible reasons identified previously, specific to the MSC, it is possible that 
due to their larger size they were becoming caught in capillaries. Data obtained showed that 
MSC were getting caught up in capillaries in all four of the experimental conditions 
investigated. Most likely the MSC are also becoming adherent within other organs, to 
confirm this after the experiment the organs could have been removed and observed to 
identify any MSCs. However, this experimental step was not carried out due to time 
constraints. MSCs being stuck within capillaries and possibly many organs would lower the 
concentration of MSCs circulating past the thrombi. Therefore, have a lower chance to 
become adherent. To support this finding, much literature has shown that MSC do not seem 
to adhere to damaged tissue (Kavanagh et al., 2013(b)). However, there is literature that 
contradicts these findings as studies have also demonstrated MSCs to have the ability to 
home in injured tissues (O'Loughlin et al., 2013).  
In vitro studies have identified how AMSC (Adipose tissue derived mesenchymal stem cells) 
should be used rather than BM derived MSC in further clinical research. This was proposed 
due to the finding that after passaging multiple times AMSC were observed to have a faster 
proliferation rate in comparison to BMSC. The study also gave supporting evidence of MSC 
to be used as a ‘therapeutic delivery vehicle’. However, research has not been carried out to 
fully confirm the efficiency of MSC as a therapeutic agent (Courtney et al., 2013). 
Literature has also shown how BM-derived MSC may be effective in treatment of non-
healing diabetic foot ulcers. The study carried out used 1x106 MSC in a rabbit ear ulcer 
model. Increased angiogenesis was found after treatment, in comparison to untreated 
wounds. From this it can be concluded that using BMSC rather than AMSC may still be 
effective. To be certain further research could be carried out using AMSC  and BMSC looking 
at diabetic foot ulcers to identify if there is any significant difference between the two. 
Furthermore, the findings from this study would need to be further researched before any 
clinical application can be made for diabetic patients. It may be a possibility that if this 
therapy is fully developed, it may be of use in healing wounds other than those seen in 
diabetics, such as in patients with coagulation related problems (O'Loughlin et al., 2013). 
Overall, between the two stem cells, HPC-7 were adherent within the cremaster and to the 
thrombi at a greater number in comparison to the MSC. However, through statistical 
analysis no significant difference between the two stem cells was found. However, similar 
intravital studies have seen significance in HPC-7 recruitment (Kavanagh et al., 2010; 
Kavanagh et al., 2011; (a) Kavanagh et al., 2013 (a)). 
In recent in vivo studies it was observed that MSC expressed adhesion molecules CD49, 
CD18, β7 and CD62L, on their cell surface (Kavanagh et al., 2013 (b)). However, adhesion 
was not seen to the endothelium even when pre-treated with H2O2 and/or TNF-α. Any 
adherence that was observed was in non injured lung tissue (Kavanagh et al., 2013 (b)).This 
also supports the finding from this investigation.  
On the other hand, although results from this investigation has shown little HPC-7 
adherence; much literature supports significant adherence of these specific stem cells 
within organs in mouse models. It was also found that HSC have a higher adherence level 
due to the intergrins CD18 expressed which are important for HSC adherence (Kavanagh et 
al., 2010; Kavanagh et al., 2011; (a) Kavanagh et al., 2013 (a)).  
Adhesion molecules play an important role in mediating interaction between cells. 
Neutrophils have been recognised to interact with platelets through P-selectin and b2 
integrin CD11b/CD18, it possible that some or all these adhesion molecules may be absent 
from the cell surface of LLC, HPC-7 and MSC, further resulting in the inability to mediate 
interaction with platelets (Brown et al., 1998; Li., 2008; Smyth et al., 2009; Yang et al., 
1999). Therefore, resulting in low levels of adherence that were observed through the 
results obtained. 
1x106 naive LLC were infused through a naive cremaster after laser induced thrombi 
formation. In the next experiment 1x106 naive LLC were infused through the cremaster 
which was stimulated with TNF-α; followed by the final set of experiments consisting of the 
infusion of 1x106 naive LLC into a cremaster which had undergone 30 minutes ischemia and 
90 minutes of reperfusion. None of the three experimental conditions investigated 
displayed any LLC adherence to the thrombi formed. However, in the ischemia reperfusion 
model LLC were identified to be adherent within other areas of the cremaster, but at a very 
low level. 
The reasons why LLC are not displaying any interaction with platelets is not very clear. Much 
literature has reported high levels of interaction between tumour cells and platelets further 
leading to a role in cancer metastasis. Many of the studies focused on cancer-platelet 
interactions are using many different cancer cell lines. It may well be a possibility that this 
particular cell line does not interact with platelets. Therefore, metastasis seen within this 
type of cancer may be mostly influenced by other microenvironmental factors, other than 
platelets.   
Additionally, other reasons for not observing any platelets-tumour interactions could be in 
relation to the chosen method of investigation. Other studies demonstrating their 
interaction have used alternative methods such as observing disseminated tumour cells in 
blood samples from cancer patients with tumour development (Buergy et al., 2012; Placke 
et al., 2012). In vitro investigation using isolated tumour cell (B16F1- melanoma cells) from 
C57BL/6 mice was also used to demonstrate tumour-platelet interactions and the increased 
metastatic ability (Amano et al., 2013). Alternatively, mouse models have also been used to 
show restoration in metastatic potential after platelet depleted animals were injected with 
tumour cells intravenously. These investigations were more directed towards investigating 
the platelet-tumour interaction in terms of the mouse model and samples used (Buergy et 
al., 2012). 
 In comparison, it is possible that the method of investigation used for this study was not 
effective as the concentration of tumour cells infused were a fraction of what would be in 
an actual tumour mouse model therefore, resulting in having a lower chance to interact 
with platelets.  Alternatively, an ideal model to confirm any interactions between LLC and 
platelets would be using a LLC tumour platelet depleted mouse model, in which platelets 
can be injected and the level of metastasis observed.  
Due to time constraints many experiments which would have been important for this 
investigation were not carried out. Looking at a few alternative cancer cell lines would have 
been valuable, as LLC did not interact with platelets but much literature has shown 
interaction between platelets and tumour cells has been observed on many occasions.  
The data obtained through all the investigations were subject to factors that may have 
influenced their outcome. Two routes of infusion were investigated; femoral artery 
cannulation and carotid artery cannulation. After statistical analysis it was clear that there 
wasn’t any significant difference between the two routes. However, it was observed that 
femoral artery infusion had shown a higher level of adherence in comparison to carotid 
artery infusion. The reason for this could be that the femoral was a more direct route into 
the cremaster for the cells to be infused through. Therefore, less cells were more likely to be 
lost elsewhere in the mouse model. Using femoral artery for cell infusion instead of the 
carotid artery maximised the percentage of cells entering the cremaster as the cremaster 
muscle itself has a lower level of blood flow in comparisons to other parts of the body and 
after the cells have passed once through the cremaster it is likely that the number of cells 
circulating within the cremaster are at a very low level, consequently lowering the likeliness 
of any cellular interactions. 
After the cells were infused through the mouse model overall adherence identified was 
quite low, therefore there is a likely possibility that the cells may be trafficking to other 
parts of the mouse model other than the cremaster muscle, such as the heart lungs and the 
kidneys as they have the highest percentage of blood flow (Elad and Einav., 2004). 
For this investigation decisions were made to help focus on the research question. The 
formation of thrombi in an arteriole was smaller in size, in comparison to a thrombi 
formation in a venule. Therefore, thrombi were mainly generated in arterioles rather than 
the venules as a part of the investigation. The larger the injured area the more the stem 
cells were expected to adhere. Also, it is possible that the stem cells would have also 
become adherent to the platelets that are already attached to the injured area.  
During this investigation, were all the other types (LLC and HPC-7) were infused at 1x106 but 
the MSC were infused at 5x105; this is a possible limitation when comparing to HPC-7 
adherence. Also, having a low number could cause an obvious decrease in the level of 
adherence due to having only 5X105 cells infused. However, in a recent study it was also 
found that increasing the number of MSC from 5x105 to 1x106 did not increase the level of 
adherence (Kavanagh et al., 2013 (b)). However, the degree of interaction could have been 
increased if the cells were administrated in multiple doses, resulting in a gradual increase in 
the circulating cells therefore increase the possibility of any interactions. 
Another factor to consider during this investigation was the cremaster muscle. Observations 
made from the preparation were limited and directed more from the center of the tissue. 
This was to avoid the damaged regions at the edges of the tissue. When the cremaster 
muscle is prepared many interconnecting vessels are a damaged which alters the flow 
distribution. This type of damage could have affected the results obtained, additionally the 
damage caused in each cremaster could have affected the flow distribution differently each 
time (Bagher et al., 2011). 
However, this particular vascular bed was good to study microcirculation via intravital 
microscopy because the preparation was versatile allowing experimental manipulations. 
Images from this preparation were of good quality and blood flow direction could easily be 
identified therefore laser injury used for this investigation was easily directed toward the 
arteriole walls as required. This vascular bed was better than other vascular beds for this 
particular investigation as cellular interactions could be more clearly identified. The 
cremaster muscle is a thin layer which can easily be prepared to study microcirculation in 
comparison to other vascular beds. The same preparation can also be done in other animal 
models such as in rats and hamsters. The preparation was also time efficient. However, the 
cremaster muscle is not commonly associated with types of injury requiring tissue 
regeneration or cancer therapy. Therefore, finding a suitable way to visualise cellular 
interactions in other vascular beds that are associated with injury may be more beneficial 
for therapeutic reasons (Bagher et al., 2011). 
The results expected in line with other literature, would have been to show homing of many 
stem cells dependant on the size of the injury. This would show that stem cells have the 
potential to adhere to the damaged tissue when and if required. However, the homing was 
expected to not be fully efficient and through method development techniques to enhance 
this process would have been examined and investigated. On the whole, this method would 
have been used primarily to confirm that stem cells do adhere to injured tissue, and the 
next step would be to investigate how to enhance the homing method of the stem cells. In 
terms of cancer cells, expected results were to see high levels of interaction between 
platelets and LLC. Having the understanding that they aid metastasis, methods of decreasing 
the interactions would have been investigated. 
However, findings that were obtained from the investigation carried out can help research 
move forward. As now it is clear that stem cells show very low adherence to platelets in the 
conditions demonstrated and the reasons for this should be investigated further. 
Additionally, it is also clear that not all types of tumour cells interact with platelets in the 
same way. Therefore, further investigation of tumour cell lines and their interactive ability 
with platelets should be investigated, to recognise the different adhesive mechanisms that 
mediate their interactions. It is a possibility that certain tumour cells can be grouped in 
terms of their style of interaction. This would further be useful in the development of 
specific therapies to halt platelet- tumour interactions. 
 
 
 
 
 
 
 
 
 
 
 
5.0 CONCLUSION 
 
This investigation required a great deal of preparation. However, studying stem cells and 
investigating their homing techniques is important. Stem cells have shown potential in 
repairing damaged tissues rapidly in diabetic patients and also in many types of bone 
injuries and injured organs. It has also been identified that types of stem cells have a 
potential in seeking out damaged cells before they become cancerous. Using different 
techniques to understanding the underlying mechanism of how stem cells actually adhere to 
the damaged tissues would lead to a better understanding, and a direction towards the 
development of techniques aiding their homing. Additionally, it would lead to using stem 
cells in therapy in patients with many different types of diseases such as, cancer, bone 
disease and diabetic wounds.  In terms of LLC no interactions were observed. As this was the 
first time LLC-platelet interactions were investigated further research using LLC tumour 
mouse models should be carried out to confirm the results from this study. Although this 
investigation has not provided any significance in platelets interacting with stem cell or 
tumour cells, much literature has demonstrated their interactions and resulting possibility 
of therapeutic effects.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  Cell Culturing- Material 
Cell Lines   HSC MSC LLC 
Base media 
Stem Pro 45ml     
MEM   47ml   
DMEM   47ml 500ml 
P/S   0.5ml 0.5ml 5ml 
Alglutamine   0.5ml 0.5ml 5ml 
Stem cell growth factor   20μl     
Growth factor T     10μl   
SPS   1.3ml     
FBS 
    0.5ml   
      50ml 
  HPC-7 MSC LLC 
Sham = Naive cells – Naive cremaster (Femoral)-infusion   N=4  N=3  N=5 
Treated = cells - H₂O₂ / Cremaster -TNFα (Carotid)-infusion  N=4  N=4          x 
Treated = cells - H₂O₂ / cremaster- TNFα (Femoral)-infusion  N=4  N=4        x 
Treated = Naive cells / cremaster- TNFα (Carotid)-infusion       x           x  N=5 
I/R Injured Cremaster = cells- H₂O₂ (Carotid)- infusion  N=5  N=4         x 
I/R Injured cremaster = Naive cells (Carotid)- infusion      x        x  N=4 
 
 (Overall  Total N= 46)   
 
 
 
 
 
 
 
 
 
LLC- IR INJURY 
Carotid infusion 
MOUSE WEIGHT (g)   SLIDE BOOK SETTINGS   THROMBI EXOGENOUS CELLS ATTACHED 
  
 
 
 
 
 
 
 
 
 
LASER  POWER FRAP SIZE FRAP REPITIONS ARTERIOLE  VENULES ARTERIOLE THROMBI NORMALISED (A) VENULE THROMBI OTHER THAN THROMBI 
1 25 75 10 15 15 0 0 0 0 1 
2 28 75 10 15 15 0 0 0 0 1 
3 26 75 10 15 15 0 0 0 0 1 
4 27 75 10 15 15 0 0 0 0 0 
Averages   26.50           15.00 0.00   0.00   0.75 
SD   
  
0.00   0.50 
SEM   0.00   0.25 
HPC-7 (H₂O₂) (IR)  
Carotid infusion 
MOUSE WEIGHT (g) 
  
SLIDE BOOK SETTINGS 
  
THROMBI EXOGENOUS CELLS ATTACHED 
LASER  POWER FRAP SIZE FRAP REPITIONS ARTERIOLE  VENULES ARTERIOLE THROMBI NORMALISED (A) VENULE THROMBI OTHER THAN THROMBI 
1 24 75 10 15 15 0 0 0 0 1 
2 26 75 10 15 16 0 0 0 0 1 
3 25 75 10 15 15 0 0 0 0 0 
4 25 75 10 15 15 0 0 0 0 0 
Averages   25.00           15.25 0.00   0.00   0.50 
SD   
  
0.00   0.58 
SEM   0.00   0.29 
MSC (H₂O₂) (IR) 
Carotid infusion 
MOUSE WEIGHT (g) 
  
SLIDE BOOK SETTINGS 
  
THROMBI EXOGENOUS CELLS ATTACHED 
LASER  POWER FRAP SIZE FRAP REPITIONS ARTERIOLE  VENULES ARTERIOLE THROMBI NORMALISED (A) VENULE THROMBI OTHER THAN THROMBI 
1 24 75 10 15 15 0 0 0 0 1 
2 27 75 10 15 15 0 0 0 0 1 
3 26 75 10 15 16 0 0 0 0 0 
4 25 75 10 15 15 0 0 0 0 0 
Averages   25.50           15.25 0.00   0.00   0.50 
SD 
  
0.00   0.58 
SEM 0.00   0.29 
LLC- 
naive 
Carotid 
infusion 
MOUSE WEIGHT (g)   SLIDE BOOK SETTINGS   THROMBI EXOGENOUS CELLS ATTACHED 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
LASER  POWER FRAP SIZE FRAP REPITIONS ARTERIOLE  VENULES ARTERIOLE THROMBI NORMALISED (A) VENULE THROMBI OTHER THAN THROMBI 
1 30 75 10 15 15 0 0 0 0 0 
2 29 75 10 15 12 0 0 0 0 0 
3 29 75 10 15 19 0 0 0 0 0 
4 27 75 10 15 20 0 0 0 0 0 
5 24 75 10 15 15 0 0 0 0 0 
Averages   27.80           16.20 0.00   0.00     
SD   
  
0.00 
  SEM   0.00 
LLC-TNFα 
Carotid 
infusion 
MOUSE WEIGHT (g) 
  
SLIDE BOOK SETTINGS 
  
THROMBI EXOGENOUS CELLS ATTACHED 
LASER  POWER FRAP SIZE FRAP REPITIONS ARTERIOLE  VENULES ARTERIOLE THROMBI NORMALISED (A) VENULE THROMBI OTHER THAN THROMBI 
1 27 75 10 15 15 0 0 0 0 0 
2 25 75 10 15 15 0 0 0 0 0 
3 26 75 10 15 12 0 0 0 0 0 
4 25 75 10 15 15 0 0 0 0 0 
5 25 75 10 15 16 0 0 0 0 0 
Averages   25.60           14.60 0.00   0.00     
SD   
  
0.00 
  SEM   0.00 
HPC-7 naive 
Femoral infusion 
MOUSE WEIGHT (g)   SLIDE BOOK SETTINGS   THROMBI EXOGENOUS CELLS ATTACHED 
   
 
 
 
 
 
 
 
 
 
 
 
LASER  POWER FRAP SIZE FRAP REPITIONS ARTERIOLE  VENULES ARTERIOLE THROMBI NORMALISED (A) VENULE THROMBI OTHER THAN THROMBI 
1 30 75 7 7 15 0 0 0 0 3 
2 29 75 10 15 16 0 2 2.5 0 1 
3 29 75 10 15 16 0 0 0 0 0 
4 27 75 10 15 15 3 0 0 0 0 
Averages   28.75           15.50 0.75   0.63   1.00 
SD   
  
1.25 
  
SEM   0.63 
HPC-7 (H₂O₂) TNFα 
Femoral infusion 
MOUSE WEIGHT (g) 
  
SLIDE BOOK SETTINGS 
  
THROMBI EXOGENOUS CELLS ATTACHED 
LASER  POWER FRAP SIZE FRAP REPITIONS ARTERIOLE  VENULES ARTERIOLE THROMBI NORMALISED (A) VENULE THROMBI OTHER THAN THROMBI 
1 27 75 10 15 9 9 0 0 0 0 
2 26 75 10 15 15 0 0 0 0 1 
3 25 75 10 15 15 0 0 0 0 1 
4 25 75 10 15 20 0 5 5 0 1 
Averages   25.75           14.75 2.25   1.25   0.75 
SD   
  
2.50 
  
SEM   1.25 
HPC-7 (H₂O₂) TNFα  
Carotid infusion 
MOUSE WEIGHT (g) 
  
SLIDE BOOK SETTINGS 
  
THROMBI EXOGENOUS CELLS ATTACHED 
LASER  POWER FRAP SIZE FRAP REPITIONS ARTERIOLE  VENULES ARTERIOLE THROMBI NORMALISED (A) VENULE THROMBI OTHER THAN THROMBI 
1 26 75 10 15 15 0 0 0 0 0 
2 28 75 10 15 20 0 0 0 0 0 
3 26 75 10 15 14 0 0 0 0 0 
4 30 75 10 15 20 1 1 1 0 0 
Averages   27.50           17.25 0.25   0.25   0.00 
SD 
  
0.50 
  
SEM 0.25 
MSC naive 
Femoral infusion 
MOUSE WEIGHT (g)   SLIDE BOOK SETTINGS   THROMBI EXOGENOUS CEL S ATTACHED 
  
LASER  POWER FRAP SIZE FRAP REPITIONS ARTERIOLE  VENULES ARTERIOLE THROMBI NORMALISED (A) VENULE THROMBI OTHER THAN THROMBI 
1 30 75 10 15 15 3 0 0 0 0 
2 29 75 10 15 15 1 0 0 0 1 
3 29 75 10 15 15 0 0 0 0 0 
Averages   29.33           15.00 1.33       0.33 
MSC (H₂O₂) TNFα 
Femoral infusion 
MOUSE WEIGHT (g) 
  
SLIDE BOOK SETTINGS 
  
THROMBI EXOGENOUS CELLS ATTACHED 
LASER  POWER FRAP SIZE FRAP REPITIONS ARTERIOLE  VENULES ARTERIOLE THROMBI NORMALISED (A) VENULE THROMBI OTHER THAN THROMBI 
1 26 75 10 15 17 1 0 0 0 0 
2 28 75 10 15 15 0 0 0 0 0 
3 26 75 10 15 14 0 0 0 0 1 
4 26 75 10 15 15 0 0 0 0 0 
Averages   26.50           15.25 0.25       0.25 
MSC (H₂O₂) TNFα 
Carotid infusion 
MOUSE WEIGHT (g) 
  
SLIDE BOOK SETTINGS 
  
THROMBI EXOGENOUS CELLS ATTACHED 
LASER  POWER FRAP SIZE FRAP REPITIONS ARTERIOLE  VENULES ARTERIOLE THROMBI NORMALISED (A) VENULE THROMBI OTHER THAN THROMBI 
1 28 75 10 15 15 0 1 1.333333333 0 0 
2 29 75 10 15 16 0 0 0 0 1 
3 28 75 10 15 17 0 0 0 0 0 
4 26 75 10 15 15 0 0 0 0 0 
Averages   27.75           15.75 0.00   0.33   0.25 
SD 
  
0.67 
  SEM 0.33 
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